News
NeuroSense says ALS drug extends survival

NeuroSense says ALS drug extends survival

NeuroSense Therapeutics is currently facing de-listing from the Nasdaq, so encouraging data from a phase 2b trial of its PrimeC drug candidate for amyotrophic lateral sclerosis (ALS) comes

R&D
Veeva R&D and Quality 2024 - Chris Moore

Veeva R&D and Quality 2024: Chris Moore

During the Veeva R&D and Quality Summit held in Madrid last month, web editor Nicole Raleigh sat down with Chris Moore, president of Europe for Veeva Systems, to discuss the event and i

Debates & Insights

News

Press Releases

Newsletters and Deep Dive
digital magazine

Views & Analysis

Deep Dive

Webinars

Podcasts

Video

White Papers

Event

Partner Content